GEHC
GE HealthCare Technologies Inc.
- PER (TTM)
- 15.22
- PER (Forward)
- 11.80
- EPS (TTM)
- -
- EPS (Forward)
- -
- PBR
- 2.79
- 시가총액
- 28.87B
- 배당수익률
- 22.00%
- 베타
- 0.87
- 1개월 수익률
- -12.95%
- 3개월 수익률
- -21.26%
- 6개월 수익률
- -15.98%
- 1년 수익률
- -7.61%
- 2년 수익률
- -
- 5일 평균거래량
- 6543040
- 60일 평균거래량
- 4354765
- 1년 평균거래량
- 3777935
- 5d/60d 거래량 비율
- 1.50×
- 60d/1y 거래량 비율
- 1.15×
- 변동성(60일, 연환산)
- 41.34%
- BB 스퀴즈 스코어
- 2.59
- SMA50 비율
- 0.90
- SMA200 비율
- 0.83
- RSI (14)
- 39
- 20일 수렴도
- 0.08
- 52주 최고
- 88.08
- 52주 최저
- 59.49
- 고점 대비
- -27.94%
- 저점 대비
- 6.70%
펀더멘털 갱신: 2026-05-10T09:08:45+00:00 · 시세 갱신: 2026-05-10T06:36:41+00:00
회사 정보
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women's health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women's health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products. The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products. The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. The company has a strategic collaboration with DeepHealth. GE HealthCare Technologies Inc. was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.